🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Antalya
Clinical trial register · Turkey

Clinical Trials in Antalya, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Turkey and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5432 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5432
Studies in scope
all four open statuses
2496
Recruiting now
open to new participants
552
Lead sponsors
across recruiting studies
Top sites
Ankara 26 Adana 21 Antalya 20 Istanbul 20 Edirne 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca31 Akdeniz University29 Eli Lilly and Company20 Janssen Research & Development, LLC15 Merck Sharp & Dohme LLC13 Clear sponsor filter
Site location
Ankara26 Adana21 Antalya20 Istanbul20 Edirne17
All 38 locations
Target enrolment
to

Trials with a site in Antalya

20 of 5432 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Turkey
Start
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Adana, Ankara, Antalya, Bornova, Hatay, Istanbul, İzmit, Mersin
2026-03-26
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Adana, Adapazarı, Ankara, Antalya, Diyarbakır, Edirne, Gaziantep, Istanbul
2025-12-12
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Adana, Afyonkarahisar, Ankara, Antalya, Çanakkale, Çorum, Eskişehir, Istanbul
2025-12-01
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Adana, Ankara, Antalya, Bornova, Diyarbakır, Edirne, Gaziantep, Pendik
2025-11-28
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Adana, Ankara, Antalya, Eskişehir, Hatay, İzmit, Malatya, Mersin
2025-11-10
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
Ankara, Antalya, Bursa, Eskişehir, Hatay, Istanbul, Izmir, İzmit
2025-06-26
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Adana, Adapazarı, Ankara, Antalya, Edirne, Gaziantep, Istanbul, Izmir
2025-03-27
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Afyonkarahisar, Ankara, Antalya, Bornova, Çorum, Edirne, Eskişehir, Gaziantep
2024-04-30
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Adana, Ankara, Antalya, Bursa, Diyarbakır, Istanbul, Izmir, Kocaeli
2023-12-21
Active, closed
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252Type 2 Diabetes, Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 2
414
Kadıköy, Adana, Antalya, Bursa, Diyarbakır, Gaziantep, Istanbul, Samsun
2023-09-21
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Adana, Ankara, Antalya, Aydin, Balçova, Bornova, Denizli, Gaziantep
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Adana, Adapazarı, Altindağ, Ankara, Antalya, Bursa, Diyarbakır, Edirne
2022-10-04
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
DrugSelpercatinib
Eli Lilly and Company
Phase 3
152
Bornova, Izmir, Karsiyaka, Adana, Ankara, Antalya, Bursa, Diyarbakır, Edirne
2021-12-20
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Stanbul, Üsküdar / Stanbul, Adana, Ankara, Antalya, Diyarbakır, Edirne, Istanbul
2021-10-04
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
996
Ankara, Antalya, Bursa, Edirne, Eskişehir, Antakya, Istanbul, Istanbul- Fatih
2020-06-22
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944Non-Small Cell Lung Cancer
DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
261
Bornova, Adana, Ankara, Antalya, Diyarbakır, Edirne, Istanbul, Izmir
2020-02-17
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Antalya, Bornova, Kocaeli, Mersin
2018-07-18
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Istanbul- Fatih, Üsküdar/stanbul, Bornova, Izmir, Karsiyaka, Ankara, Adana, Antalya, Edirne
2017-07-12
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
DrugsRamucirumab·Gemcitabine·Cisplatin
Eli Lilly and Company
Phase 2
309
Adana, Ankara, Antalya, Edirne, Istanbul
2016-05-19
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631Non Small Cell Lung Cancer
DrugsErlotinib·Abemaciclib
Eli Lilly and Company
Phase 3
453
Ankara, Antalya, Edirne, Istanbul, Izmir
2014-10-03
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Turkish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-turkey/city/antalya

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Turkey and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,432 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Antalya that also match the filters currently applied.

How many clinical trials are recruiting in Antalya?

8 of the 20 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Antalya), 20 studies
PhaseStudiesRecruitingShare
Phase 315575%
Phase 25325%

Most active sponsors

Lead sponsors with the most studies (Antalya)
Lead sponsorStudiesRecruiting
Eli Lilly and Company208
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.